Policy & Regulation
FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer
20 February 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has accepted its New D...
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
20 February 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that that the US Food and Drug Administration (FDA) has approved Venc...
Moleculin exercises warrants for USD8.3m gross proceeds
20 February 2026 - Phase 3 clinical stage pharmaceutical company Moleculin Biotech Inc (Nasdaq:MBRX) announced on Thursday that it has entered into agreements with certain holders of its existing warr...
Eupraxia Pharmaceuticals prices USD55m public offering
20 February 2026 - Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) (TSX:EPRX), a Canada-based clinical-stage biotechnology company, announced on Thursday the pricing of its USD55m public offering of common...
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
20 February 2026 - Biopharmaceutical company Lario Therapeutics announced on Thursday that it has received a total of USD2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's R...
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
19 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that the European Medicines Agency has validated a Type II variation application for Enhertu (tras...